File SF5290 ("Requires disclosure of pharmaceutical marketing spending") is before the Minnesota Legislature and has not been decided. Latest step (May 13, 2026): Introduction and first reading.
Minnesota file SF5290, before the Minnesota Legislature. Still to be decided as of 2026-05-13.
See how much drugmakers spend advertising medicines Patients and doctors gain access to pharmaceutical marketing expenditure data, making it easier to identify which companies spend heavily on promotion versus research.
Increased transparency in drug pricing and promotion Public disclosure of marketing costs may reduce information asymmetry between drugmakers and consumers, potentially supporting policy discussions about medication affordability and prescription patterns.
Addition requirement for certain pharmaceutical marketing expenses
Read the official record for SF5290
See everything up for a vote · This week in Minnesota · See what we have filed with the clerk